Ark Invest Goes Against the Grain: Wood Bets on Nvidia and the Gene-Editing Arena
Ark Invest's Cathie Wood added to existing holdings, including Nvidia (NVDA), Broadcom (AVGO), and Intellia Therapeutics (NTLA). Nvidia reported strong Q2 results with $96.2B revenue and raised guidance. Broadcom expects 85% revenue growth. Intellia Therapeutics received a Buy rating with a $24 price target. Ark's Genomic Revolution ETF (ARKG) gained 64% YTD.
How this was made
The 30-second read
Why it matters
The earnings beat and guidance from Nvidia provide a fresh catalyst for traders, while Broadcom's upcoming report and Intellia's upgrade add sector breadth.
Market read
Ark's positioning underscores confidence in AI and biotech, offering actionable trade ideas on Nvidia, Broadcom, and Intellia.
What to watch
Potential supply‑chain constraints for AI chips and regulatory hurdles for gene‑editing therapies.
Background
Ark Invest continues to add to its high‑growth holdings after strong earnings from Nvidia and upgrades to Intellia.
Ticker impact
Nvidia reported FY2027 Q2 results beating expectations with 106% YoY revenue growth and raised FY2028 guidance to 70% revenue growth.
Potential short-term rally, target above current levels.
Revenue and EPS far exceeded consensus; guidance lifts expectations for FY2028.
Broadcom is slated to report Q2 results with consensus expecting 85% revenue growth, and Ark may add to its position.
Possible upside if results exceed consensus; otherwise limited move.
Guidance is forward‑looking; no actual numbers released yet.
Intellia Therapeutics received an analyst upgrade to Buy with a $24 price target, despite being down 50% from its 2025 highs.
Modest upside toward $24 target.
Upgrade provides a new catalyst; however, profitability remains distant.
Market effects
Strong AI‑related earnings reinforce bullish outlook for semiconductor and biotech sectors.
U.S. tech and biotech indices may see upward pressure.
Highlights continued global demand for AI chips and gene‑editing therapies.
Counterpoint
High valuations may limit upside; a pullback could occur if guidance proves unsustainable.
Key entities
- personCathie Wood
Founder and CEO of Ark Invest
- companyNvidia
AI chipmaker reporting FY2027 Q2 results
- companyBroadcom
Semiconductor firm expected to report Q2 results
- companyIntellia Therapeutics
Gene‑editing biotech receiving an upgrade
